Table 3.
Predictors of Cutaneous Hypersensitivity Reaction in Children Chronically on Glucocorticoid Therapy
| Variable | Univariate OR (95% CI) | P | Multivariate OR (95% CI) | P |
|---|---|---|---|---|
| Trimethoprim- sulfamethoxazole exposure | 3.39 (2.77–4.15) | <.001 | 3.20 (2.62–3.92) | <.001 |
| Current glucocorticoid exposurea | 3.53 (2.69–4.64) | <.001 | 3.49 (2.66–4.58) | <.001 |
| Additional immunosuppressant exposure | 1.01 (0.64–1.58) | .97 | ||
| Age (continuous) | 1.00 (0.98–1.01) | .47 | ||
| Sex (female) | 0.78 (0.69–0.88) | <.001 | 0.80 (0.70–0.90) | <.001 |
| Race | ||||
| White | Reference | Reference | ||
| Black | 0.65 (0.52–0.82) | <.001 | 0.65 (0.52–0.82) | <.001 |
| Hispanic | 0.83 (0.68–1.02) | .08 | 0.84 (0.68–1.03) | .09 |
| Asian | 0.90 (0.64–1.28) | .56 | 0.93 (0.65–1.32) | .68 |
| Geographic regionb | ||||
| 1 | Reference | |||
| 2 | 0.84 (0.67–1.04) | .11 | ||
| 3 | 0.89 (0.73–1.09) | .26 | ||
| 4 | 1.03 (0.79–1.33) | .84 | ||
aCurrent glucocorticoid exposure indicates that the patient filled a prescription for glucocorticoid in the same month in which they had the outcome.
bRegions according to the US Census: Region 1, CT, MA, ME, NH, NJ, NY, PA, RI, and VT; region 2, IA, IL, IN, KS, MI, MN, MO, NE, ND, OH, SD, and WI; Region 3, AL, AR, DE, DC, FL, GA, KY, LA, MD, MS, NC, OK, SC, TN, TX, and VA; and Region 4, AK, AZ, CA, CO, HI, ID, MT, NM, NV, OR, WA, and WY.